To validate these survival results in vivo, we transplanted patient 2018-136 cells with relapsed Ph+ (BCR-ABL1), IKZF1, ΔCDKN2A/B, and ΔPAX5 leukemia into NSG mice, stratified mice into six groups (five mice per group) post leukemic development and administered either vehicle, IODVA1 (4 mM), dasatinib or ponatinib (0.5 mM), and the IODVA1 + dasatinib or IODVA1 + ponatinib combinations via subcutaneous osmotic pumps for 4 weeks. The gene discussed is IKZF1; the disease is leukemia.